CD8A and neoplasm: This approach not only improved the pharmacokinetic stability and tumor penetrance of both drugs, but co-delivery produced a synergistic improvement in the TME CD8+/Foxp3+ ratio, DC intercalation, and tumor control in a KPC mouse model.